{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:40:49Z","timestamp":1778614849030,"version":"3.51.4"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","award":["07901"],"award-info":[{"award-number":["07901"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>People with PsA are at increased risk of cardiovascular disease. The objective of this study was to quantify the risk of myocardial infarction (MI), stroke and revascularizations in people with apremilast-treated PsA compared with patients receiving other PsA treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a cohort study of 68\u00a0678 patients with PsA treated with apremilast, TNF inhibitor (TNF-i) biologics, IL-17 or -12\/23 biologics, conventional DMARDs or CS in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. Cases were patients with MI, stroke or revascularization. We calculated incidence rates (IRs) and incidence rate ratios for each outcome by exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 292 MI, 151 stroke and 475 revascularizations cases. IRs for MI were lowest for users of TNF-i biologics [1.4 per 1000 person-years (PY)] and similar for all other treatments, including apremilast, ranging from 1.8 to 3.8 per 1000 PY. IRs were similar for all treatments for both stroke (0.1\u20131.6 per 1000 PY) and revascularization (3.1\u20135.1 per 1000 PY). IRs for apremilast were 2.5 per 1000 PY for MI, 1.6 per 1000 PY for stroke and 3.3 per 1000 PY for revascularization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with treated PsA, IRs of MI, stroke and revascularization were low for all systemic treatments evaluated. Although the number of events was small, apremilast exposure did not signal potential acute cardiovascular harm and was not associated with a material increase in the risk of these serious cardiac events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa683","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T19:14:34Z","timestamp":1602098074000},"page":"1926-1931","source":"Crossref","is-referenced-by-count":29,"title":["The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids"],"prefix":"10.1093","volume":"60","author":[{"given":"Rebecca","family":"Persson","sequence":"first","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina Wilcox","family":"Hagberg","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Qian","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Vasilakis-Scaramozza","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-1067","authenticated-orcid":false,"given":"Susan","family":"Jick","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program, Lexington, MA, USA"},{"name":"Epidemiology, Boston University School of Public Health, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"key":"2021040620372673600_keaa683-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021040620372673600_keaa683-B2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdv.12163","article-title":"Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review","volume":"27","author":"Horreau","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021040620372673600_keaa683-B3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021040620372673600_keaa683-B4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021040620372673600_keaa683-B5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jbspin.2019.12.004","article-title":"Cardiovascular risk in psoriatic arthritis, a narrative review","volume":"87","author":"Verhoeven","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2021040620372673600_keaa683-B6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/pds.4617","article-title":"Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data","volume":"27","author":"Ammann","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021040620372673600_keaa683-B7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate","volume":"76","author":"Wu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021040620372673600_keaa683-B8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study","volume":"273","author":"Ahlehoff","year":"2013","journal-title":"J Intern Med"},{"key":"2021040620372673600_keaa683-B9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021040620372673600_keaa683-B10","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.34335","article-title":"Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study","volume":"64","author":"Chen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021040620372673600_keaa683-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1669-x","article-title":"Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study","volume":"20","author":"Lee","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021040620372673600_keaa683-B12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1926\/36913320\/keaa683.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1926\/36913320\/keaa683.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T23:39:51Z","timestamp":1617752391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/4\/1926\/5960200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,11,7]]},"published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa683","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,11,7]]}}}